Glucose Health, Inc.

As of June 30, 2018, Glucose Health, Inc. carries a market capitalization of 466,758.15, placing it among publicly traded companies globally. Its enterprise value stands at 981,919.15, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2018, Glucose Health, Inc. has 6.22M shares outstanding.

As of June 30, 2018, Glucose Health, Inc. trades at a trailing price-to-earnings ratio of 5.10. The price-to-sales ratio is 2.19, and the price-to-book ratio stands at -0.95.

As of June 30, 2018, Glucose Health, Inc. trades at an EV/EBITDA multiple of 31.18 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.24 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Glucose Health, Inc. trades at an EV/FCF ratio of 70.24, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 981,919.15 versus a market cap of 466,758.15, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2018, Glucose Health, Inc. maintains a current ratio of 0.27, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -114.70, indicating conservative leverage, while an interest coverage ratio of 2.44 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2018. Return on invested capital (ROIC) is negative at -48.77, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 88.32, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -142.94, pointing to unprofitable operations over the period. The company generates approximately 54,996.33 in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Glucose Health, Inc.'s stock has gained approximately 1000.00% over the past 52 weeks. The 50-day moving average sits at 0.36, while the 200-day moving average is 0.33.

Over the twelve months ended June 30, 2018, Glucose Health, Inc. generated 164,989.00 in revenue and converted that into 70,950.00 in net income, yielding earnings per share of 0.01. EBITDA reached 31,491.00, while operating income came in at 31,431.00.

As of June 30, 2018, Glucose Health, Inc. holds 29,326.00 in cash and equivalents against 431,287.00 in total debt, resulting in a net debt position of 401,961.00. Total book value stands at -489,207.00, with working capital of -376,157.00 providing operational flexibility.

Glucose Health, Inc. produced 1,088.00 in operating cash flow over the twelve months ended June 30, 2018.

Over the twelve months ended June 30, 2018, Glucose Health, Inc. posted a gross margin of 62.23, reflecting its pricing power and cost economics. The operating margin of 19.05 and net profit margin of 43.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2018. Free cash flow yield stands at 0.30, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -16.93, meaning Glucose Health, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Glucose Health, Inc.'s most recent stock split took place on November 17, 2014 with a 50:1 split ratio.

As of June 30, 2018, Glucose Health, Inc. has an Altman Z-Score of -61.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.